SCHEMBL6936253

SCHEMBL6936253

NC1CCN(c2ncnc3c2C(c2ccccc2)=CCS3)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT2 P31751 4/20 0.41
GSK3B P49841 2/20 0.41
KIT P10721 2/20 0.41
CKS1B P61024 1/20 0.41
SKP1 P63208 1/20 0.41
SKP2 Q13309 1/20 0.41
AURKA O14965 2/20 0.40
CHEK1 O14757 2/20 0.40
CHEK2 O96017 2/20 0.40
CDC7 O00311 2/20 0.40
MARK3 P27448 2/20 0.40
STK3 Q13188 2/20 0.40
PLK4 O00444 1/20 0.40
PDPK1 O15530 1/20 0.40
JAK2 O60674 1/20 0.40
ROCK2 O75116 1/20 0.40
PAK4 O96013 1/20 0.40
EGFR P00533 1/20 0.40
NTRK1 P04629 1/20 0.40
PRKCG P05129 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6838303 0.68 MEN1 (0.66) AURKAFGFR1MAPK1KDRLMNA
SCHEMBL23579855 0.68 GPR119 (0.48) GSK3BAURKACHEK1CHEK2CDC7
SCHEMBL4432115 0.68 LMNA (0.72) AURKAAURKBLMNA
SCHEMBL30034822 0.68 GPR119 (0.48) GSK3BAURKACHEK1CHEK2CDC7
SCHEMBL1003329 0.67 STK3 (0.81) GSK3BKITAURKACHEK1CHEK2
SCHEMBL4435525 0.66 MEN1 (0.65) MAPK1LIMK1LMNA
SCHEMBL2798904 0.66 LMNA (0.71) AKT2GSK3BKITLMNARAB9A
SCHEMBL1267673 0.62 NPSR1 (0.74) CKS1BSKP1SKP2MAPK1KDR
SCHEMBL4193100 0.61 HTR2C (0.65) AKT2GSK3BKITCHEK1CHEK2
SCHEMBL4245389 0.61 HTR2C (0.65) AKT2GSK3BKITNPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040138238-A1 Substituted aminopyrimidine compounds as neurokinin antagonists PREDIX PHARMACEUTICALS HOLDINGS, INC. 2004-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138238-A1 Substituted aminopyrimidine compounds as neurokinin antagonists TACR1, GRPR, BDKRB1 AKT2 2111/4885GSK3B 1528/4885KIT 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.